Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes

被引:32
|
作者
Smeeton, F. [2 ]
Moradie, F. Shojaee [3 ]
Jones, R. H. [3 ]
Westergaard, L. [4 ]
Haahr, H. [4 ]
Umpleby, A. M. [3 ]
Russell-Jones, D. L. [1 ,3 ]
机构
[1] Royal Surrey Cty Hosp, CEDAR Ctr, Guildford GU2 7XX, Surrey, England
[2] Nevill Hall Hosp, Dept Med, Abergavenny, Mons, Wales
[3] Univ Surrey, Dept Endocrinol & Diabet, Postgrad Med Sch, Surrey, England
[4] Novo Nordisk AS, Insulin Clin Pharmacol, DK-2880 Bagsvaerd, Denmark
关键词
Hepatoselectivity; Hypoglycaemia; Insulin detemir; Liver; Stable isotopes; ANALOG; RESPONSES; RISK;
D O I
10.1007/s00125-009-1487-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis We compared the symptoms of hypoglycaemia induced by insulin detemir (NN304) (B29Lys(epsilon-tetradecanoyl), desB30 human insulin) and equally effective doses of neutral protamine Hagedorn (NPH) insulin in relation to possible differential effects on hepatic glucose production and peripheral glucose uptake. Methods After overnight intravenous infusion of soluble human insulin 18 participants with type 1 diabetes received subcutaneous injections of NPH insulin or insulin detemir (0.5 U/kg body weight) on separate occasions in random order. During the ensuing gradual development of hypoglycaemia cognitive function and levels of counter-regulatory hormones were measured and rates of endogenous glucose production and peripheral glucose uptake continuously evaluated using a primed constant infusion of [6,6-H-2(2)] glucose. The study was terminated when plasma glucose concentration had fallen to 2.4 mmol/l or had reached a minimum at a higher concentration. Results During the development of hypoglycaemia no difference between the two insulin preparations was observed in symptoms or hormonal responses. Significant differences were seen in rates of glucose flux. At and below plasma glucose concentrations of 3.5 mmol/l suppression of endogenous glucose production was greater with insulin detemir than with NPH insulin, whereas stimulation of peripheral glucose uptake was greater with NPH insulin than with insulin detemir. Conclusions/interpretation In participants with type 1 diabetes subcutaneously injected insulin detemir exhibits relative hepatoselectivity compared with NPH insulin, but symptoms of hypoglycaemia and hormonal counter-regulation are similar.
引用
收藏
页码:2317 / 2323
页数:7
相关论文
共 50 条
  • [21] Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial
    Bartley, P. C.
    Bogoev, M.
    Larsen, J.
    Philotheou, A.
    DIABETIC MEDICINE, 2008, 25 (04) : 442 - 449
  • [22] Non-Inferiority of Insulin Glargine Versus Insulin Detemir on Blood Glucose Variability in Type 1 Diabetes Patients: A Multicenter, Randomized, Crossover Study
    Renard, Eric
    Dubois-Laforgue, Daniele
    Guerci, Bruno
    DIABETES TECHNOLOGY & THERAPEUTICS, 2011, 13 (12) : 1213 - 1218
  • [23] Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin
    De Leeuw, I
    Vague, P
    Selam, JL
    Skeie, S
    Lang, H
    Draeger, E
    Elte, JWF
    DIABETES OBESITY & METABOLISM, 2005, 7 (01) : 73 - 82
  • [24] Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100 U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy
    Owens, David R.
    Traylor, Louise
    Mullins, Peter
    Landgraf, Wolfgang
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 124 : 57 - 65
  • [25] Cerebral Blood Flow and Glucose Metabolism in Appetite-Related Brain Regions in Type 1 Diabetic Patients After Treatment With Insulin Detemir and NPH Insulin A randomized controlled crossover trial
    van Golen, Larissa W.
    IJzerman, Richard G.
    Huisman, Marc C.
    Hensbergen, Jolanda F.
    Hoogma, Roel P.
    Drent, Madeleine L.
    Lammertsma, Adriaan A.
    Diamant, Michaela
    DIABETES CARE, 2013, 36 (12) : 4050 - 4056
  • [26] Symptoms, hormones, and glucose fluxes during a gradual hypoglycaemia induced by intraperitoneal vs venous insulin infusion in type I diabetes
    Selam, JL
    Medlej, R
    Mbemba, J
    Chevalier, A
    Guyon, F
    Ashworth, L
    Slama, G
    DIABETIC MEDICINE, 1995, 12 (12) : 1102 - 1109
  • [27] Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Reply to Chantelau E [letter] and Currie CJ [letter]
    Rosenstock, J.
    Fonseca, V.
    McGill, J. B.
    Riddle, M.
    Halle, J. -P.
    Hramiak, I.
    Johnston, P.
    Davis, M.
    DIABETOLOGIA, 2009, 52 (10) : 2236 - 2239
  • [28] Cerebral dysfunction in type 1 diabetes: effects of insulin, vascular risk factors and blood-glucose levels
    Brands, AMA
    Kessels, RPC
    de Haan, EHF
    Kappelle, LJ
    Biessels, GJ
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 490 (1-3) : 159 - 168
  • [29] Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study
    Takahashi, Hiroshi
    Nishimura, Rimei
    Onda, Yoshiko
    Ando, Kiyotaka
    Tsujino, Daisuke
    Utsunomiya, Kazunori
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (04) : 335 - 342
  • [30] Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia
    Brosen, Julie Maria Boggild
    Agesen, Rikke Mette
    Kristensen, Peter Lommer
    Alibegovic, Amra Ciric
    Andersen, Henrik Ullits
    Beck-Nielsen, Henning
    Gustenhoff, Peter
    Hansen, Troels Krarup
    Hedetoft, Christoffer
    Jensen, Tonny
    Stolberg, Charlotte Ron
    Juhl, Claus Bogh
    Lerche, Susanne Sogaard
    Norgaard, Kirsten
    Parving, Hans-Henrik
    Tarnow, Lise
    Thorsteinsson, Birger
    Pedersen-Bjergaard, Ulrik
    DIABETES OBESITY & METABOLISM, 2023, 25 (06) : 1557 - 1565